Cell-free DNA (cfDNA) collection tubes have important applications in multiple fields. The following are some of the main application areas:

Early Tumor Screening: By detecting cfDNA in the blood, specific gene mutations, abnormal DNA methylation, and other markers released by tumor cells into the blood can be identified. This is helpful for early detection of tumors when they are still small and asymptomatic, such as in the early screening of various cancers including lung cancer, colorectal cancer, and liver cancer.
Dynamic Tumor Monitoring: During the treatment of tumor patients, blood samples are regularly collected using cfDNA collection tubes, and changes in tumor-related markers in cfDNA are monitored. This can promptly reflect the development, recurrence, or metastasis of the tumor, assisting doctors in adjusting the treatment plan.
Individualized Tumor Treatment: Conducting genetic testing on cfDNA to analyze the gene mutation spectrum of tumor cells can help select targeted drugs, immunotherapeutic drugs, etc. for patients, achieving precise individualized treatment, improving the treatment effect, and reducing adverse reactions.

Detection of Fetal Chromosomal Aneuploidy: Pregnant women’s peripheral blood contains fetal-derived cfDNA. By collecting the blood of pregnant women using cfDNA collection tubes and analyzing the content and characteristics of fetal cfDNA in it through technologies such as high-throughput sequencing, it is possible to detect whether the fetus has chromosomal aneuploidy abnormalities such as trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. This is a non-invasive, safe, and accurate prenatal screening method.
Detection of Monogenic Genetic Diseases: For some monogenic genetic diseases with known pathogenic genes, such as hemophilia and thalassemia, genetic diagnosis can be carried out by analyzing the fetal cfDNA in the blood of pregnant women to determine whether the fetus carries the pathogenic gene, providing an important basis for prenatal diagnosis and genetic counseling.

Monitoring of Rejection Reaction: After organ transplantation, the cfDNA in the recipient’s blood comes from both the transplanted organ cells and the recipient’s own cells. By detecting changes in the content, gene mutations, DNA methylation, and other characteristics of cfDNA, the rejection reaction of the transplanted organ can be detected early, and intervention measures can be taken in a timely manner to improve the survival rate of the transplanted organ.
Assessment of Graft Injury: Monitoring cfDNA can help understand whether there are conditions such as ischemia-reperfusion injury and infection in the transplanted organ, evaluate the functional status of the graft, and assist doctors in adjusting the immunosuppressive regimen and treatment strategy in a timely manner.

Diagnosis and Prognosis Assessment of Myocardial Infarction: After a myocardial infarction, necrotic myocardial cells will release cfDNA into the blood. Detecting the level of cfDNA and related markers is helpful for the early diagnosis of myocardial infarction and for assessing the degree of myocardial injury and the prognosis, providing a reference for clinical treatment.
Monitoring of Heart Failure: In patients with heart failure, the level of cfDNA is related to the severity of the disease and the prognosis. By regularly collecting blood to detect cfDNA, the changes in the condition of heart failure can be monitored, and the adjustment of the treatment plan can be guided.

Pathogen Detection: When certain infectious diseases occur, the DNA of pathogens may appear in the patient’s blood as part of the cfDNA. Using cfDNA collection tubes to collect samples, and through genetic testing technologies, the specific DNA sequences of pathogens can be quickly detected, enabling the rapid diagnosis of the infecting pathogens, such as the diagnosis of viral, bacterial, and fungal infections.
Monitoring of Infectious Disease Condition: During the treatment of infections, monitoring the change in the content of pathogen DNA in cfDNA can evaluate the treatment effect, determine whether the infection is under control, and guide the determination of clinical medication and the treatment course.

Drug Research and Development: In drug clinical trials, samples are collected using cfDNA collection tubes, and the changes in cfDNA during the drug treatment process are monitored. cfDNA can be used as a biomarker for evaluating the efficacy of drugs, helping researchers understand the mechanism of action, efficacy, and safety of drugs, and accelerating the drug research and development process.
Forensic Identification: In some forensic cases, the cfDNA in the blood samples collected by cfDNA collection tubes can be used for individual identification, paternity testing, etc., providing a scientific basis for case-solving and judicial trials.